Drug class
Synthetic serine protease inhibitor; anticoagulant and protease-modulating agent
Mechanism of action
A rapidly hydrolysed synthetic serine protease inhibitor that inhibits thrombin, plasmin and kallikrein, limiting proteolysis and aspects of coagulation and fibrinolysis. It does not inhibit all serine proteases, and activity is short-lived because of rapid plasma metabolism.
General use cases
- Treatment of acute pancreatitis and disseminated intravascular coagulation in countries where gabexate mesilate is authorised.
- Regional anticoagulation during haemodialysis in selected settings, according to local practice and product authorisation.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
